

Supporting Information

Intraperitoneal *versus* intravenous administration of Flamma[®]-conjugated PEG-alendronate-coated upconversion nanoparticles in mice pancreatic cancer model

Taras Vasylyshyn^a, Vitalii Patsula^a, David Větvička^b, Oleksandr Shapoval^a, Jan Pankrác^c, Martina Kabešová^b, Jiří Beneš^b, Daniel Horák^a

^a Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského nám. 2, 162 06 Prague 6, Czech Republic

^b Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Salmovská 1, 120 00 Prague 2, Czech Republic

^c Center for Advanced Preclinical Imaging, First Faculty of Medicine, Charles University, Salmovská 3, 120 00 Prague 2, Czech Republic




Figure S1. Formula of Flamma[®] 749 sulfo-NHS ester.




Figure S2. UV-Vis spectra of UCNPs, UCNP@Ale-PEG, UCNP@Ale-PEG-Flamma[®] and Flamma[®].




Figure S3. Upconversion photoluminescence emission spectra of aqueous UCNP@Ale-PEG-Flamma[®] dispersions (2 mg/ml) excited at 980 nm with different power densities. The inset shows the dependence of peak intensity on particle concentrations.




Figure S4. Upconversion photoluminescence emission spectra of aqueous UCNP@Ale-PEG-Flamma[®] dispersions at different concentrations; excitation at 980 nm, power density 2.11 W/cm². The inset shows the dependence of peak intensity on laser power density.